申请人:SMITH KLINE & FRENCH LABORATORIES
LIMITED
公开号:EP0244201A2
公开(公告)日:1987-11-04
A compound of formula (1)
and pharmaceutically acceptable acid addition salts thereof in which
R1 is hydrogen or can together with R3 form a -(CH2)n- group where n is 2, 3 or 4;
R3 is hydrogen, C1-4alkyl, halogen, or amino, or R3 together with R' can form a-(CH2)n- group;
R4 is hydroxy or a phosphate group;
R5 is hydrogen, C1-4alkyl, halogen, or amino, provided that
R3 and R5 are not both hydrogen;
m is 2, or 4; and
R is a 2, 3, or 4-pyridyl or pyridyl N-oxide or N-C1-C4alkylpyridone group optionally substituted by one or two groups selected from C1-4alkyl, Cl-4alkoxy, hydroxy and hydroxymethyl.
Also disclosed are pharmaceutical compositions containing compounds of formula (1), methods for their preparation and their use as histamine H1-antagonists.
一种式(1)化合物
及其药学上可接受的酸加成盐,其中
R1 是氢或可与 R3 一起形成-(CH2)n-基团,其中 n 是 2、3 或 4;
R3是氢、C1-4烷基、卤素或氨基,或R3与R'一起可形成-(CH2)n-基团;
R4 是羟基或磷酸基;
R5 是氢、C1-4 烷基、卤素或氨基,条件是
R3 和 R5 不能都是氢;
m 是 2 或 4;以及
R 是 2、3 或 4-吡啶基或吡啶基 N-氧化物或 N-C1-C4 烷基吡啶酮基团,可任选被一或两个选自 C1-4烷基、Cl-4烷氧基、羟基和羟甲基的基团取代。
还公开了含有式(1)化合物的药物组合物、其制备方法及其作为组胺 H1 拮抗剂的用途。